NU7441 (KU-57788)

Name: NU7441 (KU-57788)
Brand: Selleck Chemicals
SKU: S2638
Rating: 5 (169 reviews)

For research use only.

Catalog No.S2638

169 publications

CAS No. 503468-95-9

NU7441 (KU-57788) is a highly potent and selective DNA-PK inhibitor with IC50 of 14 nM and also inhibits mTOR and PI3K with IC50 of 1.7 μM and 5 μM in cell-free assays, respectively. It reduces the frequency of NHEJ while increasing the rate of HDR following Cas9-mediated DNA cleavage.

Selleck's NU7441 (KU-57788) has been cited by 169 publications

Immunity, 2021, S1074-7613(21)00069-8

PubMed: 33667382 ( click the link to review the publication )

Cell Res, 2021, 10.1038/s41422-021-00528-3

PubMed: 34239070 ( click the link to review the publication )

Nature, 2020, 10.1038/s41586-020-2960-y

PubMed: 33239783 ( click the link to review the publication )

Nature, 2019, 74(7779):571-574

PubMed: 31645724 ( click the link to review the publication )

Cancer Cell, 2019, 36(2):179-193

PubMed: 31378681 ( click the link to review the publication )

Cell, 2019, 36(2):179-193

PubMed: 28162770 ( click the link to review the publication )

Cancer Cell, 2018, 34(3):396-410

PubMed: 30205044 ( click the link to review the publication )

Nat Biotechnol, 2017, 35(5):463-474

PubMed: 28319085 ( click the link to review the publication )

Sci Transl Med, 2021, 13(600)eabc7275

PubMed: 34193614 ( click the link to review the publication )

Sci Adv, 2021, 7(25)eabg6680

PubMed: 34144993 ( click the link to review the publication )

J Clin Invest, 2021, 131(11)146256

PubMed: 34060485 ( click the link to review the publication )

Nucleic Acids Res, 2021, gkab262

PubMed: 33877327 ( click the link to review the publication )

Nucleic Acids Res, 2021, 49(9):5095-5105

PubMed: 33963863 ( click the link to review the publication )

J Exp Clin Cancer Res, 2021, 40(1):224

PubMed: 34225780 ( click the link to review the publication )

Cancers (Basel), 2021, 13(4)830

PubMed: 33669398 ( click the link to review the publication )

Int J Biol Sci, 2021, 17(4):1026-1040

PubMed: 33867826 ( click the link to review the publication )

Int J Biol Sci, 2021, 17(4): 1026-1040

PubMed: N/A ( click the link to review the publication )

Acta Pharmacol Sin, 2021, 10.1038/s41401-020-00577-1

PubMed: 33414509 ( click the link to review the publication )

Biochem Biophys Res Commun, 2021, 553:51-57

PubMed: 33756345 ( click the link to review the publication )

Mol Biol Rep, 2021, 10.1007/s11033-020-06124-9

PubMed: 33389482 ( click the link to review the publication )

FEBS Open Bio, 2021, 10.1002/2211-5463.13198

PubMed: 33999508 ( click the link to review the publication )

Commun Biol, 2021, 4(1):484

PubMed: 33875784 ( click the link to review the publication )

Sci Transl Med, 2021, 13(580)eabc4465

PubMed: 33568520 ( click the link to review the publication )

Nucleic Acids Res, 2021, gkab051

PubMed: 33591315 ( click the link to review the publication )
Blood, 2020, 5 pii: blood

PubMed: 32369572 ( click the link to review the publication )

Adv Sci (Weinh), 2020, 7(20):2000157

PubMed: 33101843 ( click the link to review the publication )

Mol Cell, 2020, S1097-2765(20)30723-1

PubMed: 33152268 ( click the link to review the publication )

Nat Commun, 2020, 11(1):6182

PubMed: 33273464 ( click the link to review the publication )

Nat Commun, 2020, 11(1):5775

PubMed: 33188175 ( click the link to review the publication )

Nucleic Acids Res, 2020, 10.1093/nar/gkaa022

PubMed: 31965183 ( click the link to review the publication )

Nucleic Acids Res, 2020, gkaa782

PubMed: 33010172 ( click the link to review the publication )

Sci Immunol, 2020, 5(43)

PubMed: 31980485 ( click the link to review the publication )

Clin Cancer Res, 2020, 10.1158/1078-0432.CCR-20-2269

PubMed: 32967938 ( click the link to review the publication )

J Cell Biol, 2020, 219(11)e202001063

PubMed: 33007086 ( click the link to review the publication )

Cell Rep, 2020, 32(8):108068

PubMed: 32846126 ( click the link to review the publication )

Cell Rep, 2020, 32(11):108140

PubMed: 32937135 ( click the link to review the publication )

Cell Rep, 2020, 33(2):108240

PubMed: 33053351 ( click the link to review the publication )

Signal Transduct Target Ther, 2020, 4;5(1):20

PubMed: 32296021 ( click the link to review the publication )

Mol Oncol, 2020, 26

PubMed: 32336009 ( click the link to review the publication )

Mol Cancer Res, 2020, 10.1158/1541-7786.MCR-19-0507

PubMed: 32229503 ( click the link to review the publication )

Front Oncol, 2020, 10:575711

PubMed: 33178606 ( click the link to review the publication )

Int J Mol Sci, 2020, 21(17)E6383

PubMed: 32887472 ( click the link to review the publication )

Int J Oncol, 2020, 57(4):939-955

PubMed: 32945394 ( click the link to review the publication )

Int J Radiat Biol, 2020, 1-7

PubMed: 33074046 ( click the link to review the publication )

J Cell Physiol, 2020, 10.1002/jcp.29927

PubMed: 32686190 ( click the link to review the publication )

Nucleic Acids Res, 2020, 48(2):736-747

PubMed: 31740976 ( click the link to review the publication )

Cancers (Basel), 2020, 12(9):E2356

PubMed: 32825402 ( click the link to review the publication )

Cancers (Basel), 2020, 12(6):1490

PubMed: 32517381 ( click the link to review the publication )
Oncotarget, 2020, 11(7):699-726

PubMed: 32133046 ( click the link to review the publication )

NAR Cancer, 2020, 2(2):zcaa006

PubMed: 32743550 ( click the link to review the publication )

Elife, 2020, 9:e57894

PubMed: 32628111 ( click the link to review the publication )

J Biol Chem, 2020, 295(1):125-137

PubMed: 31753920 ( click the link to review the publication )

Int J Mol Med, 2020, 45(6):1673-1684

PubMed: 32186748 ( click the link to review the publication )

Cell Rep, 2020, 32(6):108018

PubMed: 32783940 ( click the link to review the publication )

Toxicol Lett, 2020, 318:104-113

PubMed: 31672611 ( click the link to review the publication )

Biomed Pharmacother, 2020, 129:110427

PubMed: 32574974 ( click the link to review the publication )

Nat Commun, 2019, 10(1):5304

PubMed: 31757956 ( click the link to review the publication )

Nat Commun, 2019, 10(1):1577

PubMed: 30952868 ( click the link to review the publication )

Nat Commun, 2019, 10(1):3925

PubMed: 31477700 ( click the link to review the publication )

Nat Commun, 2019, 10(1):2866

PubMed: 31253785 ( click the link to review the publication )

Clin Cancer Res, 2019, 25(18):5608-5622

PubMed: 31266829 ( click the link to review the publication )

Genes Dev, 2019, 33(17-18):1175-1190

PubMed: 31395742 ( click the link to review the publication )

Haematologica, 2019, 104(11):2225-2240

PubMed: 30819918 ( click the link to review the publication )

J Cell Biol, 2019, 218(7):2113-2123

PubMed: 31123184 ( click the link to review the publication )

Cell Rep, 2019, 29(11):3708-3725.e5

PubMed: 31825846 ( click the link to review the publication )

Int J Cancer, 2019, 10.1002/ijc.32558

PubMed: 31283004 ( click the link to review the publication )

Oncogene, 2019, 38(14):2451-2463

PubMed: 30532030 ( click the link to review the publication )

Cancers (Basel), 2019, 11(9)

PubMed: 31480356 ( click the link to review the publication )

Br J Cancer, 2019, 121(7):600-610

PubMed: 31481733 ( click the link to review the publication )

FASEB J, 2019, 33(1):1138-1150

PubMed: 30106602 ( click the link to review the publication )

FASEB J, 2019, 33(11):11668-11681

PubMed: 31348687 ( click the link to review the publication )

FASEB J, 2019, 33(6):6778-6788

PubMed: 30807703 ( click the link to review the publication )
PLoS Genet, 2019, 15(2):e1007925

PubMed: 30716077 ( click the link to review the publication )

J Environ Manage, 2019, 244:77-82

PubMed: 31108313 ( click the link to review the publication )

Mol Cancer Res, 2019, 17(12):2457-2468

PubMed: 31551253 ( click the link to review the publication )

Toxicol Sci, 2019, 10.1093/toxsci/kfz178

PubMed: 31388677 ( click the link to review the publication )

Int J Mol Sci, 2019, 20(24)E6316

PubMed: 31847370 ( click the link to review the publication )

J Biol Chem, 2019, 294(8):2827-2838

PubMed: 30598506 ( click the link to review the publication )

Mol Cell Biol, 2019, 39(24)e00181-19

PubMed: 31591143 ( click the link to review the publication )

J Pharmacol Exp Ther, 2019, 371(2):320-326

PubMed: 31455631 ( click the link to review the publication )

Retrovirology, 2019, 16(1):13

PubMed: 31036006 ( click the link to review the publication )

Front Physiol, 2019, 10:616

PubMed: 31178753 ( click the link to review the publication )

BMC Pulm Med, 2019, 19(1-:165

PubMed: 31464599 ( click the link to review the publication )

Mol Biol Rep, 2019, 10.1007/s11033-019-04605-0

PubMed: 31020489 ( click the link to review the publication )

Mol Biol Rep, 2019, 10.1007/s11033-019-05105-x

PubMed: 31583565 ( click the link to review the publication )

Mol Med Rep, 2019, 20(4):3609-3616

PubMed: 31485633 ( click the link to review the publication )

FEBS Open Bio, 2019, 9(7):1315-1326

PubMed: 31141305 ( click the link to review the publication )

Nucleic Acids Res, 2019, 47(21):10977-10993

PubMed: 31612207 ( click the link to review the publication )

Nucleic Acids Res, 2019, 47(18):9467-9479

PubMed: 31396623 ( click the link to review the publication )

Nucleic Acids Res, 2019, 47(16):8838-8859

PubMed: 31329944 ( click the link to review the publication )

Cell Res, 2018, 28(7):756-770

PubMed: 29844578 ( click the link to review the publication )

Nat Commun, 2018, 9(1):5351

PubMed: 30559436 ( click the link to review the publication )

Cell Rep, 2018, 24(4):987-1000

PubMed: 30044993 ( click the link to review the publication )

Int J Cancer, 2018,

PubMed: 29363109 ( click the link to review the publication )

Cell Death Dis, 2018, 9(9):931

PubMed: 30209297 ( click the link to review the publication )

FASEB J, 2018, 32(4):1818-1829

PubMed: 29162700 ( click the link to review the publication )
Mol Cancer Ther, 2018, 17(12):2551-2563

PubMed: 30217967 ( click the link to review the publication )

Hum Mol Genet, 2018, 27(23):4024-4035

PubMed: 30107443 ( click the link to review the publication )

Mol Cancer Res, 2018, 16(3):428-438

PubMed: 29222170 ( click the link to review the publication )

Mol Cancer Res, 2018, 16(8):1241-1254

PubMed: 29739874 ( click the link to review the publication )

DNA Repair (Amst), 2018, 68:68-74

PubMed: 30017059 ( click the link to review the publication )

Mol Biol Cell, 2018, 29(15):1786-1797

PubMed: 29897835 ( click the link to review the publication )

Int J Mol Sci, 2018,

PubMed: 30115874 ( click the link to review the publication )

Sci Rep, 2018, 8(1):9685

PubMed: 29946146 ( click the link to review the publication )

Nucleic Acids Res, 2018, 46(10):5050-5060

PubMed: 29660033 ( click the link to review the publication )

Nucleic Acids Res, 2018, 46(17):8926-8939

PubMed: 30113698 ( click the link to review the publication )

Sci Rep, 2018, 8(1):14421

PubMed: 30258062 ( click the link to review the publication )

Biochem Biophys Rep, 2018, 16:115-121

PubMed: 30417129 ( click the link to review the publication )

Oncotarget, 2018, 9(9):8560-8572

PubMed: 29492217 ( click the link to review the publication )

JCI Insight, 2018, 3(3)98096

PubMed: 29415883 ( click the link to review the publication )

Nucleic Acids Res, 2017, 45(1):244-254

PubMed: 28069995 ( click the link to review the publication )

Cancer Immunol Res, 2017, 5(9):790-803

PubMed: 28775208 ( click the link to review the publication )

Cancer Res, 2017, 77(17):4567-4578

PubMed: 28698210 ( click the link to review the publication )

Cancer Res, 2017, 77(18):4745-4754

PubMed: 28754673 ( click the link to review the publication )

J Cell Biol, 2017, 216(3):623-639

PubMed: 28228534 ( click the link to review the publication )

EMBO Rep, 2017, 18(8):1412-1428

PubMed: 28615293 ( click the link to review the publication )

Cell Death Discov, 2017, 3:17072

PubMed: 29090098 ( click the link to review the publication )

J Biol Chem, 2017, 292(30):12424-12435

PubMed: 28592488 ( click the link to review the publication )

Mol Biol Cell, 2017, 28(26):3756-3772

PubMed: 29074567 ( click the link to review the publication )

Int J Biochem Cell Biol, 2017, 92:164-172

PubMed: 28827033 ( click the link to review the publication )
Radiat Res, 2017, 188(6):597-604

PubMed: 28952912 ( click the link to review the publication )

PLoS One, 2017, 12(7):e0181608

PubMed: 28750002 ( click the link to review the publication )

DNA Repair (Amst), 2017, 54:30-39

PubMed: 28448822 ( click the link to review the publication )

Oncotarget, 2017, 8(52):90037-90049

PubMed: 29163809 ( click the link to review the publication )

Oncotarget, 2017, 8(2):2916-2935

PubMed: 27935866 ( click the link to review the publication )

Nat Cell Biol, 2016, 18(11):1196-1207

PubMed: 27723717 ( click the link to review the publication )

blood, 2016, 10.1182/blood-2016-02-700328

PubMed: ( click the link to review the publication )

Blood, 2016, 128(4):574-83

PubMed: 27235137 ( click the link to review the publication )

Nat Commun, 2016, 7:12880

PubMed: 27634057 ( click the link to review the publication )

Oncogene, 2016, 35(5):577-586

PubMed: 25893305 ( click the link to review the publication )

Cancer Lett, 2016, 383(1):41-52

PubMed: 27693461 ( click the link to review the publication )

Cell Death Dis, 2016, 7(7):e2316

PubMed: 27468692 ( click the link to review the publication )

Sci Rep, 2016, 6:22972

PubMed: 27026501 ( click the link to review the publication )

Cell Cycle, 2016, 15(1):84-94

PubMed: 26771713 ( click the link to review the publication )

PLoS One, 2016, 11(12):e0167454

PubMed: 27907109 ( click the link to review the publication )

PLoS One, 2016, 11(5):e0155230

PubMed: 27153109 ( click the link to review the publication )

PLoS One, 2016, 11(9):e0163049

PubMed: 27643854 ( click the link to review the publication )

Nucleic Acids Res, 2016, 44(11):5204-17

PubMed: 27001513 ( click the link to review the publication )

Oncotarget, 2016, 7(38):60807-60822

PubMed: 27602502 ( click the link to review the publication )

Nucleic Acids Res, 2016, 44(8):3695-712

PubMed: 26843428 ( click the link to review the publication )

Oncotarget, 2016, 7(40):65504-65513

PubMed: 27602767 ( click the link to review the publication )

Mutat Res Genet Toxicol Environ Mutagen, 2016, 795:1-6

PubMed: 26774662 ( click the link to review the publication )

Nat Cell Biol, 2015, 17(9):1158-68

PubMed: 26237645 ( click the link to review the publication )

Leukemia, 2015, 29(5):1133-42

PubMed: 25371178 ( click the link to review the publication )
Genome Med, 2015, 10.1186/s13073-015-0215-6

PubMed: 26307031 ( click the link to review the publication )

Mol Cancer Ther, 2015, 14(8):1896-906

PubMed: 26026052 ( click the link to review the publication )

Mol Cancer Res, 2015, 13(1):120-9

PubMed: ( click the link to review the publication )

Mol Cancer Res, 2015, 13(1):120-9

PubMed: 25232030 ( click the link to review the publication )

J Biol Chem, 2015, 290(46):27545-56

PubMed: 26420486 ( click the link to review the publication )

Cancer Biol Ther, 2015, 16(11):1585-92

PubMed: 26382920 ( click the link to review the publication )

Cell Cycle, 2015, 14(23):3713-24

PubMed: 26505547 ( click the link to review the publication )

PLoS ONE, 2015,

PubMed: 26065416 ( click the link to review the publication )

Anticancer Res, 2015, 35(7):3829-38

PubMed: 26124328 ( click the link to review the publication )

Oncotarget, 2015, 6(16):14005-25

PubMed: 26087309 ( click the link to review the publication )

Nucleic Acids Res, 2014, 42(12):7776-92

PubMed: 24906880 ( click the link to review the publication )

Nucleic Acids Res, 2014, 42(9):5616-32

PubMed: 24598253 ( click the link to review the publication )

Genes Dev, 2014, 28(8):875-87

PubMed: 24700029 ( click the link to review the publication )

Cancer Res, 2014, 74(16):4282-94

PubMed: 24894717 ( click the link to review the publication )

Oncogene, 2014, 10.1038/onc.2014.268

PubMed: 25132265 ( click the link to review the publication )

ACS Chem Biol, 2014, 9(5):1160-71

PubMed: 24568369 ( click the link to review the publication )

Toxicol Sci, 2014, 10.1093/toxsci/kfu207

PubMed: 25288669 ( click the link to review the publication )

Biosci Rep, 2014, 34(3)

PubMed: 24844881 ( click the link to review the publication )

Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis, 2014,

PubMed: ( click the link to review the publication )

Uppsala University, 2014, Department of Radiology

PubMed: ( click the link to review the publication )

Mutat Res, 2014, 769:1-10

PubMed: 25771720 ( click the link to review the publication )

Nucleic Acids Res, 2013, 41(22):10157-69

PubMed: 24021630 ( click the link to review the publication )

Nucleic Acids Res, 2013, 41(7):4080-92

PubMed: 23449221 ( click the link to review the publication )

Nucleic Acids Res, 2013, 41(15):7378-86

PubMed: 23775790 ( click the link to review the publication )
Int J Radiat Oncol Biol Phys, 2013, 88(2):385-94

PubMed: 24411611 ( click the link to review the publication )

Purity & Quality Control

Choose Selective DNA-PK Inhibitors

Biological Activity

Description

Targets

DNA-PK ^[1] (Cell-free assay)	mTOR ^[1] (cell-free assay)	PI3K ^[1] (cell-free assay)
14 nM	1.7 μM	5 μM

In vitro

NU7441 increases the persistence of γH2AX foci after ionizing radiation–induced or etoposide-induced DNA damage. NU7441 (0.5 μM or 1 μM) appreciably increases G2-M accumulation induced by ionizing radiation, etoposide, and doxorubicin in both SW620 and LoVo cells. ^[2] NU7441 causes persistence of doxorubicin- and ionising radiation-induced DNA double-strand break and also slightly decreases homologous recombination activity DNA-PK-proficient M059-Fus-1 and DNA-PK-deficient M059 J human tumour cells. ^[3] NU7441 inhibits UV-induced RPA p34 hyperphosphorylation in a dose-dependent manner both in cells lacking and cells expressing polymerase η. ^[4] NU7441 increases levels of fludarabine-induced γH2AX foci and correspondingly decreased fludarabine-induced cell death in chronic lymphocytic leukemia cells. ^[5] NU7441 also inhibits mitoxantrone-induced DNA-PKcs autophosphorylation and repair in chronic lymphocytic leukemia cells. ^[6] It reduces the frequency of NHEJ while increasing the rate of HDR following Cas9-mediated DNA cleavage^[7].

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Activity Description	PMID
NCI-H1770	NIrRWWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			M3vTXWlEPTB;MD6wNlE1OyEQvF2=	MmHyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg5Pjd6Lze+V2FPT0WUPD;hQi=>
A172	MmTQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MUHJR\|UxRTBwMUWzNVYh\|ryP	NXz4WG9{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh6Nke4M{c,W0GQR1XSQE9iRg>?
NCI-H526	NUHITnBsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NWjRW\|RLUUN3ME2wMlI5PDB5IN88US=>	NU[xd4FRRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh6Nke4M{c,W0GQR1XSQE9iRg>?
HDLM-2	M1LlfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MX7JR\|UxRTBwM{KzOFUh\|ryP	M3zhflxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QDZ5OD:nQnNCVkeHUkyvZV4>
HuO-3N1	NVywfFY3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NFzo[JpKSzVyPUCuOFY3OzZizszN	NUXRU41pRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh6Nke4M{c,W0GQR1XSQE9iRg>?
NCI-SNU-1	M{G5W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MVTJR\|UxRTBwNkC5PVQh\|ryP	NFXWOVE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
SK-N-AS	M3jFSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NETMV5dKSzVyPUCuOlIzOTZizszN	MWq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFg3PzhxJ{7TRW5ITVJ:L3G+
LoVo	NETNR4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			M2\DfWlEPTB;MD64Olc1QSEQvF2=	NXfkW\|dCRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh6Nke4M{c,W0GQR1XSQE9iRg>?
LAMA-84	M4D3e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NF3lfmpKSzVyPUCuPVg5OzNizszN	M4DuO\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QDZ5OD:nQnNCVkeHUkyvZV4>
CTB-1	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MlrJTWM2OD1zLkGxOVQ3KM7:TR?=	NF;1O5A9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
KP-N-YS	MnLFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MUTJR\|UxRTFwMUSyN\|Eh\|ryP	NHvxOXI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
HH	NFPrSnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			M4X2W2lEPTB;MT6xPFA6OyEQvF2=	MlLEQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg5Pjd6Lze+V2FPT0WUPD;hQi=>
CHL-1	NUfUV5FlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NY\tVpRSUUN3ME2xMlIyOzZ6IN88US=>	MnTQQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg5Pjd6Lze+V2FPT0WUPD;hQi=>
NB7	NWniZmY{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MUfJR\|UxRTFwMkS3OFUh\|ryP	M1u0UFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QDZ5OD:nQnNCVkeHUkyvZV4>
HL-60	NYTrUHlsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			M16yPWlEPTB;MT6zPFE6KM7:TR?=	MoK5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg5Pjd6Lze+V2FPT0WUPD;hQi=>
639-V	NFzOV3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NHPVR4hKSzVyPUGuOFQyOjhizszN	MYi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFg3PzhxJ{7TRW5ITVJ:L3G+
NCI-H1793	NHvReFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MkexTWM2OD1zLkS1PFQh\|ryP	M33Gd\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QDZ5OD:nQnNCVkeHUkyvZV4>
NEC8	NFjEXm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MlvJTWM2OD1zLkW1N\|Uh\|ryP	NFH5R4U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
PA-1	Mn[4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MmLiTWM2OD1zLkW4Nlk1KM7:TR?=	NH\5eY49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
D-423MG	M1TvPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			M{e5OGlEPTB;MT62PVM3OSEQvF2=	NYXDc4piRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh6Nke4M{c,W0GQR1XSQE9iRg>?
NCI-H292	NYDoeGs5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			M{fFNmlEPTB;MT63OFAyOyEQvF2=	NXLIRVBsRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh6Nke4M{c,W0GQR1XSQE9iRg>?
SK-MEL-1	NV7wOI11T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			M1u2b2lEPTB;MT63PVQ4QSEQvF2=	MorOQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg5Pjd6Lze+V2FPT0WUPD;hQi=>
LB2241-RCC	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MlraTWM2OD1{LkG0NVQ3KM7:TR?=	NXjueHpzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh6Nke4M{c,W0GQR1XSQE9iRg>?
SK-MEL-3	NIqxcmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			M1\zW2lEPTB;Mj6xOlQ6KM7:TR?=	MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFg3PzhxJ{7TRW5ITVJ:L3G+
MHH-PREB-1	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			M1fYSmlEPTB;Mj6xOlYxQSEQvF2=	NGjFWYg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
BFTC-905	M3;heWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MV7JR\|UxRTJwMU[2PFch\|ryP	M4KxOlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QDZ5OD:nQnNCVkeHUkyvZV4>
Ramos-2G6-4C10	NWHXSYNFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MknpTWM2OD1{LkG5PVA6KM7:TR?=	NHrMOXA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
G-361	NVfo[Hk5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MWnJR\|UxRTJwMkG2PEDPxE1?	MX:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFg3PzhxJ{7TRW5ITVJ:L3G+
MOLT-4	NYjVVnBRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			M2HxWWlEPTB;Mj6yNVg5QCEQvF2=	MV:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFg3PzhxJ{7TRW5ITVJ:L3G+
DEL	MlTDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			M2n5SmlEPTB;Mj6zOVU3PCEQvF2=	NFHvUHY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
MV-4-11	NXzrU3NoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MoTYTWM2OD1{LkO3N\|kh\|ryP	MX68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFg3PzhxJ{7TRW5ITVJ:L3G+
SK-NEP-1	M1njbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			M3KxVmlEPTB;Mj6zPFc5OyEQvF2=	MlPUQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg5Pjd6Lze+V2FPT0WUPD;hQi=>
RS4-11	NX22fodST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NHHZdlhKSzVyPUKuOVYxOjNizszN	NVfKS3RmRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh6Nke4M{c,W0GQR1XSQE9iRg>?
HuH-7	NELPe5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			Mn;kTWM2OD1{LkW2O\|AzKM7:TR?=	NIT0fXQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
A101D	NYTzSXU1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			M3rFNWlEPTB;Mj62NVM{QCEQvF2=	M33yUFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QDZ5OD:nQnNCVkeHUkyvZV4>
KG-1	NF;C[llIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MWDJR\|UxRTJwNke5NlQh\|ryP	MWG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFg3PzhxJ{7TRW5ITVJ:L3G+
KALS-1	NI\ldGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			M{TGW2lEPTB;Mj62PVY{OyEQvF2=	Mn2yQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg5Pjd6Lze+V2FPT0WUPD;hQi=>
VMRC-RCZ	MnnXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NEDhb\|JKSzVyPUKuO\|c{OjhizszN	MWq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFg3PzhxJ{7TRW5ITVJ:L3G+
SK-UT-1	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			M2TTZWlEPTB;Mz6xOVMyKM7:TR?=	NUjsWWdkRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh6Nke4M{c,W0GQR1XSQE9iRg>?
SW962	NHvoVYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			Mki1TWM2OD1\|LkKwN\|UzKM7:TR?=	M3y5bFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QDZ5OD:nQnNCVkeHUkyvZV4>
DBTRG-05MG	NELYeFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MUnJR\|UxRTNwMkiwPFUh\|ryP	M{XGPFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QDZ5OD:nQnNCVkeHUkyvZV4>
PANC-08-13	MnzsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NF;R[YJKSzVyPUOuOFEzPzhizszN	MUW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFg3PzhxJ{7TRW5ITVJ:L3G+
QIMR-WIL	NHiwZ2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MYTJR\|UxRTNwNEGzOFEh\|ryP	NFnOSlQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
SK-MEL-30	M17rbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			Mor6TWM2OD1\|LkSyOVk5KM7:TR?=	MVG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFg3PzhxJ{7TRW5ITVJ:L3G+
697	M4r6bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			M4XJ[mlEPTB;Mz60OFk6OyEQvF2=	M3vxWFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QDZ5OD:nQnNCVkeHUkyvZV4>
NY	NYf0NmhrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			Ml3TTWM2OD1\|LkS1NFIzKM7:TR?=	Mme2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg5Pjd6Lze+V2FPT0WUPD;hQi=>
ES7	NXnHfWFNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MUfJR\|UxRTNwNE[3Nlkh\|ryP	MmjKQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg5Pjd6Lze+V2FPT0WUPD;hQi=>
JVM-3	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MX7JR\|UxRTNwNEiwO\|ch\|ryP	NU\IToRnRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh6Nke4M{c,W0GQR1XSQE9iRg>?
U031	M2HqS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NH;FN4pKSzVyPUOuOVk{PjhizszN	M2HMeFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QDZ5OD:nQnNCVkeHUkyvZV4>
BHT-101	M3rFdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NIC2d4pKSzVyPUOuOVk6QDVizszN	NIP4U2E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
8305C	NVXRV2tzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MXHJR\|UxRTNwNkG3N\|Yh\|ryP	M2\p[VxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QDZ5OD:nQnNCVkeHUkyvZV4>
MG-63	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NHGzfnZKSzVyPUOuOlI3PzZizszN	Ml7oQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg5Pjd6Lze+V2FPT0WUPD;hQi=>
NOS-1	Ml65S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NH[2O4lKSzVyPUOuOlU{OTJizszN	NHvIU5A9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
YH-13	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NGPOd4FKSzVyPUOuPFcyQDlizszN	M2\iS\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QDZ5OD:nQnNCVkeHUkyvZV4>
LXF-289	M2jQcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NIPiNZFKSzVyPUOuPVExPDFizszN	NIX0V4c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
GOTO	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			M1LiRWlEPTB;Mz65NVQ6KM7:TR?=	NXHMbXh2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh6Nke4M{c,W0GQR1XSQE9iRg>?
EKVX	M4PpXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NEjq[2pKSzVyPUSuNlI2OjRizszN	Ml3TQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg5Pjd6Lze+V2FPT0WUPD;hQi=>
CAL-51	MnzPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MUXJR\|UxRTRwMkS4OVQh\|ryP	MWO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFg3PzhxJ{7TRW5ITVJ:L3G+
AN3-CA	M1:4V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7			M17OdWlEPTB;ND6yOVgyOyEQvF2=	MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFg3PzhxJ{7TRW5ITVJ:L3G+
IA-LM	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			M3jxOGlEPTB;ND6yO\|k{PSEQvF2=	MYq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFg3PzhxJ{7TRW5ITVJ:L3G+
KU-19-19	NILKfVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NIHzfphKSzVyPUSuN\|I6OjFizszN	NV\vdWI3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh6Nke4M{c,W0GQR1XSQE9iRg>?
A704	MoPoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			M3rBNGlEPTB;ND60NFg5QCEQvF2=	MWS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFg3PzhxJ{7TRW5ITVJ:L3G+
RH-18	M1rheGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NGXkbYlKSzVyPUSuOFQ6PTNizszN	NWXUSYpRRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh6Nke4M{c,W0GQR1XSQE9iRg>?
IST-MEL1	MnroS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MV\JR\|UxRTRwNUiyOlMh\|ryP	MlfOQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg5Pjd6Lze+V2FPT0WUPD;hQi=>
LU-134-A	M3;Xemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MoPOTWM2OD12LkW5Olg2KM7:TR?=	M4fZT\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QDZ5OD:nQnNCVkeHUkyvZV4>
SF126	M3HtV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7			M1uy[2lEPTB;ND62NFcyPSEQvF2=	MmXpQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg5Pjd6Lze+V2FPT0WUPD;hQi=>
EFO-27	NIDCZVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NE\oOGRKSzVyPUSuOlY2OjVizszN	MmPDQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg5Pjd6Lze+V2FPT0WUPD;hQi=>
SN12C	M1mycGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MnTJTWM2OD12LkexPFk5KM7:TR?=	Mn7LQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg5Pjd6Lze+V2FPT0WUPD;hQi=>
L-363	M1Lwemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MV3JR\|UxRTRwN{exNVYh\|ryP	NWHvXoF[RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh6Nke4M{c,W0GQR1XSQE9iRg>?
MEL-HO	M1\DXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NUfHO4JCUUN3ME20Mlc4QTh7IN88US=>	M1fWS\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QDZ5OD:nQnNCVkeHUkyvZV4>
TYK-nu	NEjacohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NFHQXJZKSzVyPUSuPFAyOjhizszN	M1rsNVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QDZ5OD:nQnNCVkeHUkyvZV4>
MDA-MB-415	NUj5c2d2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			M1;UNWlEPTB;NT6wNFMyPCEQvF2=	M13tN\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QDZ5OD:nQnNCVkeHUkyvZV4>
HCC70	M3iyOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			M{fmSGlEPTB;NT6wN\|k{QSEQvF2=	MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFg3PzhxJ{7TRW5ITVJ:L3G+
IGROV-1	M4ezWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MoXtTWM2OD13LkK1NlkzKM7:TR?=	MlTuQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg5Pjd6Lze+V2FPT0WUPD;hQi=>
NCI-H1355	NV73R5BtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MX3JR\|UxRTVwMkm2JO69VQ>?	MV:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFg3PzhxJ{7TRW5ITVJ:L3G+
23132-87	M3jMNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MYrJR\|UxRTVwM{KwNlQh\|ryP	NWnZ[IJxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh6Nke4M{c,W0GQR1XSQE9iRg>?
NB69	NIXXU\|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			M17lWmlEPTB;NT6zNlQzKM7:TR?=	Mk\pQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg5Pjd6Lze+V2FPT0WUPD;hQi=>
HSC-2	Mn3aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NYOyd4pqUUN3ME21MlQyPzd\|IN88US=>	NXPpNYE1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh6Nke4M{c,W0GQR1XSQE9iRg>?
KYSE-410	NEjaUm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NYH6UGdsUUN3ME21MlQ4PjN4IN88US=>	NFG3e\|g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
GCIY	NX;vc5oxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NYjWWZJGUUN3ME21MlUyOzd6IN88US=>	MoqxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg5Pjd6Lze+V2FPT0WUPD;hQi=>
A427	M2nEW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7			M{DYbWlEPTB;NT61N\|Y3OSEQvF2=	MYK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFg3PzhxJ{7TRW5ITVJ:L3G+
ChaGo-K-1	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MVTJR\|UxRTVwNU[1PVkh\|ryP	NF\uWoI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
PFSK-1	M3rTeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NVfwcoFZUUN3ME21MlYzOTl2IN88US=>	M4jNNFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QDZ5OD:nQnNCVkeHUkyvZV4>
MLMA	NEDUO5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NYnuc2NiUUN3ME21Mlg{PjB4IN88US=>	M3TReVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QDZ5OD:nQnNCVkeHUkyvZV4>
RVH-421	M4\JTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			M{jRUmlEPTB;Nj6wO\|M{QCEQvF2=	NIHmRms9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
LB1047-RCC	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MojXTWM2OD14LkG3OVIzKM7:TR?=	NVTOPJp6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh6Nke4M{c,W0GQR1XSQE9iRg>?
MHH-NB-11	NUjzSHk{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NFzMdnZKSzVyPU[uN\|I4OjFizszN	M{O3OlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QDZ5OD:nQnNCVkeHUkyvZV4>
J-RT3-T3-5	NGDjUFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NULhPFBCUUN3ME22MlY{OjlzIN88US=>	M2nEV\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QDZ5OD:nQnNCVkeHUkyvZV4>
UM-UC-3	NHzEN3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NIr4U4hKSzVyPU[uOlQ{OzRizszN	MVW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFg3PzhxJ{7TRW5ITVJ:L3G+
IST-SL1	MnnsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MY\JR\|UxRTZwNkmzOlkh\|ryP	MVi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFg3PzhxJ{7TRW5ITVJ:L3G+
NB14	MmHjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			M{\Vc2lEPTB;Nj63PVc3OSEQvF2=	NUOweVlLRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh6Nke4M{c,W0GQR1XSQE9iRg>?
NBsusSR	NFTuO4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			Ml76TWM2OD14LkiyOVAzKM7:TR?=	NVK3UHRYRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh6Nke4M{c,W0GQR1XSQE9iRg>?
D-263MG	NFnRfFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			M1rGNmlEPTB;Nj65NVA3QCEQvF2=	NYLk[HFmRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh6Nke4M{c,W0GQR1XSQE9iRg>?
NCI-H2347	MmjZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NETFfHhKSzVyPU[uPVMzOTNizszN	NGK4T2g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
ES8	Mo\IS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MnK2TWM2OD14Lkm3OVg5KM7:TR?=	MlPLQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg5Pjd6Lze+V2FPT0WUPD;hQi=>
786-0	NWriXmVuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MnH6TWM2OD15LkC5O\|g3KM7:TR?=	MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFg3PzhxJ{7TRW5ITVJ:L3G+
EPLC-272H	NHS1XHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NIrGUYZKSzVyPUeuNVYzPDZizszN	MYG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFg3PzhxJ{7TRW5ITVJ:L3G+
CAPAN-1	M{jqe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NYT1NFJZUUN3ME23MlI1OzV7IN88US=>	MlLqQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg5Pjd6Lze+V2FPT0WUPD;hQi=>
NCI-H82	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			M4\EPGlEPTB;Nz6yOlY2QSEQvF2=	MVe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFg3PzhxJ{7TRW5ITVJ:L3G+
G-402	MmDrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MlHvTWM2OD15LkOwNFUyKM7:TR?=	NGrPR3I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
SW982	NYX6OYdyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MkHDTWM2OD15LkOwNlA{KM7:TR?=	Mk\LQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg5Pjd6Lze+V2FPT0WUPD;hQi=>
OVCAR-4	M4\0UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MYnJR\|UxRTdwM{GzNlgh\|ryP	NG\Xco49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
KARPAS-299	Ml;PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NIe5PFlKSzVyPUeuN\|I3OjJizszN	NXT6b2N4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh6Nke4M{c,W0GQR1XSQE9iRg>?
MIA-PaCa-2	NXvVVGVtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			M3Hob2lEPTB;Nz6zOlgzOyEQvF2=	M3zUZVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QDZ5OD:nQnNCVkeHUkyvZV4>
AU565	M1mybGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			M4fzeWlEPTB;Nz61PVg{OyEQvF2=	NHr4SHQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
GAMG	NFLPUVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			Mo\rTWM2OD15Lk[0NVMyKM7:TR?=	NHPEUlE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
HuO9	NIH0XodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MoXITWM2OD15LkexO\|Q{KM7:TR?=	NUDvcZNORGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh6Nke4M{c,W0GQR1XSQE9iRg>?
ACN	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MWnJR\|UxRTdwN{SzN{DPxE1?	NF7PV2w9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
RO82-W-1	M1rGfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NUPSR4tiUUN3ME23Mlc1PTN\|IN88US=>	NWnl[3Y5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh6Nke4M{c,W0GQR1XSQE9iRg>?
NKM-1	M{\lcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			M2WxbWlEPTB;Nz63OFk2PSEQvF2=	NV3MTYRuRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh6Nke4M{c,W0GQR1XSQE9iRg>?
CAL-12T	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MV;JR\|UxRTdwOUSzOVIh\|ryP	NHvSdJg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
FADU	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NUTtOJVLUUN3ME24MlA{PjV2IN88US=>	Mnz0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg5Pjd6Lze+V2FPT0WUPD;hQi=>
NCI-H28	MkSzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NHX5ZnZKSzVyPUiuNVY6PjJizszN	NWjScZJ1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh6Nke4M{c,W0GQR1XSQE9iRg>?
LCLC-97TM1	NHj6Z4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NXTTcJJCUUN3ME24MlIyOTJ{IN88US=>	MkjKQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg5Pjd6Lze+V2FPT0WUPD;hQi=>
CHP-134	M{\EO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NYTUN5ZqUUN3ME24MlI1OTh3IN88US=>	NFO2dYQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
HT-1080	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			M1nDNWlEPTB;OD6yOVA6OyEQvF2=	M4DIRVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QDZ5OD:nQnNCVkeHUkyvZV4>
PC-3	NGjhSG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NH;tUW5KSzVyPUiuNlc{QTJizszN	NHiwcIE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
SNU-449	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			M2rwfGlEPTB;OD6yO\|k{KM7:TR?=	M2P0RlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QDZ5OD:nQnNCVkeHUkyvZV4>
VA-ES-BJ	NIXV[JlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			M1G5NGlEPTB;OD6zOFY5PiEQvF2=	NHHmS2M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
HT	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NWfvWpFlUUN3ME24MlM3PDlizszN	NXfXTmp5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh6Nke4M{c,W0GQR1XSQE9iRg>?
HOS	NY\GVmRrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MmOzTWM2OD16LkO3OVg6KM7:TR?=	NFXmSFc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
KNS-62	M{DZbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			M1nkOWlEPTB;OD6zO\|c3OiEQvF2=	NXv6VlNIRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh6Nke4M{c,W0GQR1XSQE9iRg>?
OAW-42	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NWrUR3N3UUN3ME24Mlk2QTZ2IN88US=>	NH[xVo49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
A549	M{\oO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MkDuTWM2OD17LkC5OlEzKM7:TR?=	MWi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFg3PzhxJ{7TRW5ITVJ:L3G+
CAKI-1	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NUnlWnN[UUN3ME25MlE3PjFizszN	MXy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFg3PzhxJ{7TRW5ITVJ:L3G+
HCC1937	M1vmUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NEfiXmFKSzVyPUmuOlk5PjVizszN	M4rONVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QDZ5OD:nQnNCVkeHUkyvZV4>
GI-ME-N	NYPTToNMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NF;6boRKSzVyPUmuO\|AyOzdizszN	NV3kXIdDRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh6Nke4M{c,W0GQR1XSQE9iRg>?
DU-4475	NXL6W\|RJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NV\oOVhmUUN3ME25Mlk3QTN7IN88US=>	MV[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFg3PzhxJ{7TRW5ITVJ:L3G+
EM-2	NWDleJZKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NX3icGhmUUN3ME2xNE4zPDJ4IN88US=>	MWG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFg3PzhxJ{7TRW5ITVJ:L3G+
NCI-H1755	NEHBdJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MV3JR\|UxRTFyLkK0Nlgh\|ryP	NX;udnB5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh6Nke4M{c,W0GQR1XSQE9iRg>?
NCI-H1437	M{nH[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MonUTWM2OD1zMD61O\|I2KM7:TR?=	NGLFdms9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
VM-CUB-1	NEfoTXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NHL1[pBKSzVyPUGwMlYyPjRizszN	NYLtcYtKRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh6Nke4M{c,W0GQR1XSQE9iRg>?
A2058	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NUDOPWJVUUN3ME2xNE43PDB2IN88US=>	M2TldFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QDZ5OD:nQnNCVkeHUkyvZV4>
BPH-1	NXf4b5F[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			M{XPd2lEPTB;MUCuO\|E1PSEQvF2=	M1P1UFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QDZ5OD:nQnNCVkeHUkyvZV4>
NB5	NX73N25jT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MYLJR\|UxRTFyLke1OVkh\|ryP	M2XS[VxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QDZ5OD:nQnNCVkeHUkyvZV4>
G-401	MnvBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NIGydpBKSzVyPUGwMlc3OjZizszN	Mli4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg5Pjd6Lze+V2FPT0WUPD;hQi=>
CAL-72	M{D3T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NWP3PWkzUUN3ME2xNE45ODl2IN88US=>	M4XDS\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QDZ5OD:nQnNCVkeHUkyvZV4>
SK-MEL-28	NHzObXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NUXXO2dRUUN3ME2xNE45OjB{IN88US=>	NHvYNHA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
C32	NHPIfphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NUjKdXJWUUN3ME2xNE45OzR5IN88US=>	M1TnPFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QDZ5OD:nQnNCVkeHUkyvZV4>
NCI-H1155	M{LoW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NGDaUGJKSzVyPUGwMlg{PzZizszN	NUHZXZN3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh6Nke4M{c,W0GQR1XSQE9iRg>?
BB49-HNC	M1LvOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MYHJR\|UxRTFyLki1PFYh\|ryP	NITWe2w9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
GMS-10	NWDVVVJ4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MWPJR\|UxRTFyLki5O\|Eh\|ryP	NGnrN\|I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
K5	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MUfJR\|UxRTFyLkmwO\|Eh\|ryP	M3jlfFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QDZ5OD:nQnNCVkeHUkyvZV4>
OS-RC-2	Ml\OS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NEXmPVhKSzVyPUGxMlA2PTlizszN	Mo[4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg5Pjd6Lze+V2FPT0WUPD;hQi=>
HTC-C3	NUTXUmZGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MnSxTWM2OD1zMT6wO\|E1KM7:TR?=	NHnk[ZI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
LB996-RCC	NImy[nBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MWnJR\|UxRTFzLkC3NlMh\|ryP	M2O4RVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QDZ5OD:nQnNCVkeHUkyvZV4>
NCI-H1563	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NVzUNlE6UUN3ME2xNU4yODFzIN88US=>	NWTTeZVuRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh6Nke4M{c,W0GQR1XSQE9iRg>?
CAL-54	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NYPneIpVUUN3ME2xNU41QDFzIN88US=>	M3\IS\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QDZ5OD:nQnNCVkeHUkyvZV4>
WM-115	MkTJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NVu1N\|ZMUUN3ME2xNU43QDJ2IN88US=>	NYrpUWtZRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh6Nke4M{c,W0GQR1XSQE9iRg>?
COLO-684	NHHtbGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MWrJR\|UxRTFzLkeyOlch\|ryP	NWX1UXdoRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh6Nke4M{c,W0GQR1XSQE9iRg>?
HOP-62	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MXTJR\|UxRTFzLke1NFgh\|ryP	MXS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFg3PzhxJ{7TRW5ITVJ:L3G+
NCI-H650	NXHUeIF6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			Mli4TWM2OD1zMT64PVYyKM7:TR?=	NXf2To9NRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh6Nke4M{c,W0GQR1XSQE9iRg>?
TE-11	NF\GW2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			Mmn0TWM2OD1zMT65N\|E2KM7:TR?=	NF\qNYU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
COLO-679	Mo[0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MUHJR\|UxRTFzLkm0OkDPxE1?	Mn3BQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg5Pjd6Lze+V2FPT0WUPD;hQi=>
FTC-133	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MlrnTWM2OD1zMj6wNFc3KM7:TR?=	MXm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFg3PzhxJ{7TRW5ITVJ:L3G+
D-283MED	NH\TNldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NV;YWFRjUUN3ME2xNk4xPTZ7IN88US=>	MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFg3PzhxJ{7TRW5ITVJ:L3G+
SK-PN-DW	NHftUIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MmPLTWM2OD1zMj6xPVAzKM7:TR?=	NGTyW3I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
BALL-1	M4e4NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NE\qZYRKSzVyPUGyMlI3PjJizszN	MkHPQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg5Pjd6Lze+V2FPT0WUPD;hQi=>
GT3TKB	MoXyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MUTJR\|UxRTF{LkOwO\|Qh\|ryP	MmHkQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg5Pjd6Lze+V2FPT0WUPD;hQi=>
HOP-92	M2f5OGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			M1;2VGlEPTB;MUKuOVI{OyEQvF2=	MoXKQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg5Pjd6Lze+V2FPT0WUPD;hQi=>
M14	NX3rVmhST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NFLtbZlKSzVyPUGzMlA{OzVizszN	MmC1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg5Pjd6Lze+V2FPT0WUPD;hQi=>
SKG-IIIa	NUTQe4Z[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NWrzSVFJUUN3ME2xN{4xPTV2IN88US=>	M4XM[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QDZ5OD:nQnNCVkeHUkyvZV4>
Becker	M3PJ[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			M13n[WlEPTB;MUOuNFU5KM7:TR?=	M13XUFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QDZ5OD:nQnNCVkeHUkyvZV4>
ES5	Ml25S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NFW1d4pKSzVyPUGzMlE{PTZizszN	MlvZQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg5Pjd6Lze+V2FPT0WUPD;hQi=>
NCI-H2030	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MnHHTWM2OD1zMz6yNFYzKM7:TR?=	MlX2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg5Pjd6Lze+V2FPT0WUPD;hQi=>
SNU-423	M4PFWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NWDzU4hZUUN3ME2xN{4{QDFizszN	NUHWU\|BZRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh6Nke4M{c,W0GQR1XSQE9iRg>?
CP50-MEL-B	M3\qcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			M4XxcmlEPTB;MUOuOlI{OiEQvF2=	NUC3cotwRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh6Nke4M{c,W0GQR1XSQE9iRg>?
NCI-H1092	M2\VPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NV72foVzUUN3ME2xN{44PDd3IN88US=>	MUm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFg3PzhxJ{7TRW5ITVJ:L3G+
8-MG-BA	NH\XVVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NHn4co1KSzVyPUGzMlc2OTNizszN	NF7RR\|M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
CAL-27	NGXnO5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MVPJR\|UxRTF2LkC3Nlch\|ryP	M2TJSFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QDZ5OD:nQnNCVkeHUkyvZV4>
AGS	NH7ZeZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NYXXVG5NUUN3ME2xOE4yOzF7IN88US=>	NV3PN\|V6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh6Nke4M{c,W0GQR1XSQE9iRg>?
MZ2-MEL	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NF7kV\|NKSzVyPUG0MlE1QDhizszN	NF;JNWU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
BFTC-909	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MXXJR\|UxRTF2LkWwOVUh\|ryP	M2Do[lxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QDZ5OD:nQnNCVkeHUkyvZV4>
D-566MG	M{TtRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			M{HYW2lEPTB;MUSuO\|cxPiEQvF2=	MYG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFg3PzhxJ{7TRW5ITVJ:L3G+
MZ7-mel	MoO4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NITZV2lKSzVyPUG1MlExPjdizszN	MVW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFg3PzhxJ{7TRW5ITVJ:L3G+
TE-5	M4jnfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MlfOTWM2OD1zNT6yN\|M{KM7:TR?=	NYPs[5pNRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh6Nke4M{c,W0GQR1XSQE9iRg>?
647-V	NIXRSFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MkTSTWM2OD1zNT6yO\|A2KM7:TR?=	Mn\tQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg5Pjd6Lze+V2FPT0WUPD;hQi=>
DMS-114	MmrUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NYLPb\|Q1UUN3ME2xOU4{OjlzIN88US=>	MXW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFg3PzhxJ{7TRW5ITVJ:L3G+
ME-180	MnnJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MnTuTWM2OD1zNT60O\|g{KM7:TR?=	NWfh[5JkRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh6Nke4M{c,W0GQR1XSQE9iRg>?
MS-1	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NH;WPHVKSzVyPUG1MlU3OjNizszN	M1rDbFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QDZ5OD:nQnNCVkeHUkyvZV4>
NUGC-3	NWC4bWt[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NVzs[GJjUUN3ME2xOU43OjR3IN88US=>	NFLL[\|c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
GB-1	M3LJVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			Mnj0TWM2OD1zNT62OFM4KM7:TR?=	NILnWng9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
LOXIMVI	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MUjJR\|UxRTF3Lki5NVkh\|ryP	M2m4WVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QDZ5OD:nQnNCVkeHUkyvZV4>
NCI-H1304	M1ezdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NFj6cIVKSzVyPUG1Mlg6OjhizszN	NHPoSWM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
KURAMOCHI	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NV3RW3ZEUUN3ME2xOU46PzFizszN	NWrpfoJRRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh6Nke4M{c,W0GQR1XSQE9iRg>?
SW1783	NFno[mxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			M3LDO2lEPTB;MU[uNFk6OyEQvF2=	M1\xOVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QDZ5OD:nQnNCVkeHUkyvZV4>
EGI-1	M1PSdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			M2DOc2lEPTB;MU[uOVM3PSEQvF2=	NW\zS4NxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh6Nke4M{c,W0GQR1XSQE9iRg>?
KGN	NUW5N2tOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NVLKfpRwUUN3ME2xOk42PTh4IN88US=>	MnGxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg5Pjd6Lze+V2FPT0WUPD;hQi=>
PANC-03-27	NXPIbWx6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MnzITWM2OD1zNj63OlYzKM7:TR?=	NWKxO3N{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh6Nke4M{c,W0GQR1XSQE9iRg>?
RH-1	M2nrRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MX3JR\|UxRTF4LkiyOUDPxE1?	MnvqQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg5Pjd6Lze+V2FPT0WUPD;hQi=>
HT-1376	NYfGZZA{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			M{nZeGlEPTB;MU[uPFQ1PiEQvF2=	NFvNPI09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
ZR-75-30	MojyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MmfwTWM2OD1zNj65N\|YyKM7:TR?=	NGrn[mY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
TI-73	NEHuS2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NHK5PIVKSzVyPUG2Mlk1ODhizszN	NW[1bGxGRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh6Nke4M{c,W0GQR1XSQE9iRg>?
TK10	NYj2RWJ3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NFqyR2RKSzVyPUG3MlAxPzlizszN	MnnKQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg5Pjd6Lze+V2FPT0WUPD;hQi=>
SW684	NF7QSGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NIe1fVhKSzVyPUG3MlAyPTRizszN	NWrpdJN6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh6Nke4M{c,W0GQR1XSQE9iRg>?
RPMI-8866	NX64SYVYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NFP2bHlKSzVyPUG3MlA3QTlizszN	NX70S4tlRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh6Nke4M{c,W0GQR1XSQE9iRg>?
LNCaP-Clone-FGC	MlPBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MVPJR\|UxRTF5LkWyNFEh\|ryP	MXm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFg3PzhxJ{7TRW5ITVJ:L3G+
NCI-H2291	MorYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NHK2SXBKSzVyPUG4MlQ{PDVizszN	NHyyUIM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
T47D	NIH1T2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NECxXIRKSzVyPUG4MlQ5QCEQvF2=	NEjIUGE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
A204	NX74ZWJ7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			Mme3TWM2OD1zOD61OFUzKM7:TR?=	NXHTNXd6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh6Nke4M{c,W0GQR1XSQE9iRg>?
HT-144	NV\PeINTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NXq5Znd{UUN3ME2xPE44PDJ5IN88US=>	MX28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFg3PzhxJ{7TRW5ITVJ:L3G+
MDA-MB-361	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MkjrTWM2OD1zOT6wO\|E1KM7:TR?=	MnSzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg5Pjd6Lze+V2FPT0WUPD;hQi=>
HCC1806	NIO3VnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MnTLTWM2OD1zOT6xOVkyKM7:TR?=	MWm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFg3PzhxJ{7TRW5ITVJ:L3G+
NCI-H596	M{\Qdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NGfuWGtKSzVyPUG5MlY{QTFizszN	NXqw[JJHRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh6Nke4M{c,W0GQR1XSQE9iRg>?
K-562	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NWXsVJdEUUN3ME2xPU45QTJ4IN88US=>	MWq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFg3PzhxJ{7TRW5ITVJ:L3G+
D-336MG	NFLzPY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NHnxeGpKSzVyPUG5Mlk{OjJizszN	MoPtQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg5Pjd6Lze+V2FPT0WUPD;hQi=>
SK-MEL-2	Mmm4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			M4mxfGlEPTB;MkCuNVU2QSEQvF2=	NYXVd\|k5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh6Nke4M{c,W0GQR1XSQE9iRg>?
HEC-1	M{LhSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			M3LDWGlEPTB;MkCuOFk4QCEQvF2=	NEHCNFY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
EW-13	Ml;QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MWLJR\|UxRTJyLkW0OFMh\|ryP	MYm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFg3PzhxJ{7TRW5ITVJ:L3G+
Hs-578-T	Mn;qS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			M3fQTGlEPTB;MkCuOVU5OyEQvF2=	NEjYUWY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
SJSA-1	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NUPVbndHUUN3ME2yNE42Pjh6IN88US=>	NF3Se5Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
RCC10RGB	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			M4TaWWlEPTB;MkCuOlcyQSEQvF2=	M1vN[VxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QDZ5OD:nQnNCVkeHUkyvZV4>
LAN-6	NGC4ZnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			M4[zUmlEPTB;MkGuNFM6PiEQvF2=	Mn\rQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg5Pjd6Lze+V2FPT0WUPD;hQi=>
NCI-H1048	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			M{\zPWlEPTB;MkGuNlI2QCEQvF2=	M{PYblxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QDZ5OD:nQnNCVkeHUkyvZV4>
CW-2	MojKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			M17XbmlEPTB;MkGuNlcxPSEQvF2=	MlHsQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg5Pjd6Lze+V2FPT0WUPD;hQi=>
HCC2157	NXHGc4hPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MnL1TWM2OD1{MT6zOkDPxE1?	NY[xVpBzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh6Nke4M{c,W0GQR1XSQE9iRg>?
EW-22	NW\sT4p1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NXT2WJV3UUN3ME2yNU4{PzZizszN	NEDhdpk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
A253	M4DkZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NX3vW5ZxUUN3ME2yNU41PDhzIN88US=>	NVvXNmJ[RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh6Nke4M{c,W0GQR1XSQE9iRg>?
BE-13	NXTjWW5yT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MmX4TWM2OD1{MT62NVE{KM7:TR?=	NXfoflgyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh6Nke4M{c,W0GQR1XSQE9iRg>?
KINGS-1	NGP0SG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NUPCUXB7UUN3ME2yNU43OzF4IN88US=>	NF3Sb409[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
ETK-1	Mn\RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NXfKbpkyUUN3ME2yNU45OTV{IN88US=>	M4DxVlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QDZ5OD:nQnNCVkeHUkyvZV4>
NCI-H2452	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NVTBSVZCUUN3ME2yNU45PjR5IN88US=>	MVe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFg3PzhxJ{7TRW5ITVJ:L3G+
HPAF-II	NV7hUWJuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MnvLTWM2OD1{MT64PVI{KM7:TR?=	NWruVHE4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh6Nke4M{c,W0GQR1XSQE9iRg>?
D-542MG	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MmjETWM2OD1{MT65NFY6KM7:TR?=	NEOxVlE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
NCI-H630	M1jIRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MXPJR\|UxRTJ{LkCyPVYh\|ryP	NWC2dJR1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh6Nke4M{c,W0GQR1XSQE9iRg>?
TGBC11TKB	MljmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			M2XDWWlEPTB;MkKuNFQ6KM7:TR?=	NHK1[4I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
BCPAP	M1nZOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			Ml7QTWM2OD1{Mj62NVEh\|ryP	M{DjOlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QDZ5OD:nQnNCVkeHUkyvZV4>
HLE	NHOwV\|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NE\SWJJKSzVyPUKyMlY6PyEQvF2=	M1PnXlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QDZ5OD:nQnNCVkeHUkyvZV4>
NCI-H727	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MXzJR\|UxRTJ{LkezOUDPxE1?	MXK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFg3PzhxJ{7TRW5ITVJ:L3G+
RD	NFLyV3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NI\V[nRKSzVyPUKyMlc2OThizszN	M1XMRVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QDZ5OD:nQnNCVkeHUkyvZV4>
NCI-H522	NHXDXm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MXnJR\|UxRTJ{Lki0N\|Eh\|ryP	MWG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFg3PzhxJ{7TRW5ITVJ:L3G+
CGTH-W-1	NIG4[pRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MoDSTWM2OD1{Mz6wOlQyKM7:TR?=	NFf5Vng9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
SK-LU-1	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			M3r6NGlEPTB;MkOuOFY5OyEQvF2=	MYq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFg3PzhxJ{7TRW5ITVJ:L3G+
BB65-RCC	MmPOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NUexWGJZUUN3ME2yN{44QDZ\|IN88US=>	M17IUlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QDZ5OD:nQnNCVkeHUkyvZV4>
HSC-3	M4GzfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			M3:xT2lEPTB;MkOuPFUzPyEQvF2=	MX[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFg3PzhxJ{7TRW5ITVJ:L3G+
SK-MES-1	MofXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MXTJR\|UxRTJ2LkCxOlEh\|ryP	MVq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFg3PzhxJ{7TRW5ITVJ:L3G+
DB	NUXWbJBpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NVTMeWRmUUN3ME2yOE4yODJ6IN88US=>	NF;yV3M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
HO-1-N-1	MoTqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MnfzTWM2OD1{ND6zNFk{KM7:TR?=	M1jaT\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QDZ5OD:nQnNCVkeHUkyvZV4>
MKN1	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MnruTWM2OD1{ND62PEDPxE1?	NXn5[G1[RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh6Nke4M{c,W0GQR1XSQE9iRg>?
MN-60	MnfZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NWrmXmZUUUN3ME2yOE45PTF7IN88US=>	NGDPcXk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
8505C	NUXoTYxYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NYK4OZZvUUN3ME2yOU4yQDR3IN88US=>	NVHzS5d[RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh6Nke4M{c,W0GQR1XSQE9iRg>?
COLO-320-HSR	Mn6wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NW\hO21VUUN3ME2yOU4zOjB6IN88US=>	NGjiOng9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
BB30-HNC	Mn7NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MlLYTWM2OD1{NT6yOFg{KM7:TR?=	NX3URZlKRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh6Nke4M{c,W0GQR1XSQE9iRg>?
KM12	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NHfoUIFKSzVyPUK1MlU5ODdizszN	NILsOnU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
NB13	M4HpOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MknpTWM2OD1{NT61PFk5KM7:TR?=	MX28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFg3PzhxJ{7TRW5ITVJ:L3G+
HCC2998	M4PJSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			M2jleWlEPTB;Mk[uNFI5OyEQvF2=	MmLMQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg5Pjd6Lze+V2FPT0WUPD;hQi=>
U-118-MG	M{n0Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MXrJR\|UxRTJ4LkC4NFgh\|ryP	Mo[zQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg5Pjd6Lze+V2FPT0WUPD;hQi=>
NB10	M{O2Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			M2jZPWlEPTB;Mk[uNlM1KM7:TR?=	NEjRfmY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
SK-LMS-1	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NFjqXnpKSzVyPUK3MlA4ODRizszN	NXnxd3R[RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh6Nke4M{c,W0GQR1XSQE9iRg>?
SW1573	MoHhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			M3[1NWlEPTB;MkeuNVEh\|ryP	NFvR[5Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
LB373-MEL-D	NX\BWWxZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			M{DGOGlEPTB;MkeuNVI6PCEQvF2=	NGjpfXU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
DK-MG	NEfFS\|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NWj2SYI3UUN3ME2yO{4yQDF5IN88US=>	MkTxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg5Pjd6Lze+V2FPT0WUPD;hQi=>
RMG-I	M3HTemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			M{DjeWlEPTB;MkeuNlAzQSEQvF2=	NUnufIN5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh6Nke4M{c,W0GQR1XSQE9iRg>?
SW1088	MmLTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NWPBZ5poUUN3ME2yO{42ODR{IN88US=>	MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFg3PzhxJ{7TRW5ITVJ:L3G+
SK-OV-3	M3LQcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MUjJR\|UxRTJ5Lke1PVMh\|ryP	MojDQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg5Pjd6Lze+V2FPT0WUPD;hQi=>
KP-N-YN	Mn7hS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MofoTWM2OD1{Nz64NFQ{KM7:TR?=	NWS4eWFnRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh6Nke4M{c,W0GQR1XSQE9iRg>?
RPMI-7951	M4SyUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NF;EUZNKSzVyPUK4MlI1PTZizszN	M{DuUFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QDZ5OD:nQnNCVkeHUkyvZV4>
CaR-1	MlWzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			M3vVfGlEPTB;MkiuOVU5OiEQvF2=	NEjTUWQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
MKN7	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MkH5TWM2OD1{OD61PVY1KM7:TR?=	M{ja[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QDZ5OD:nQnNCVkeHUkyvZV4>
CHP-212	NVz4SpI{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MVvJR\|UxRTJ6Lke0NFEh\|ryP	NXr2R2RNRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh6Nke4M{c,W0GQR1XSQE9iRg>?
KYSE-450	NH;kfXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NWDnUlRYUUN3ME2yPE45ODlzIN88US=>	Mor3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg5Pjd6Lze+V2FPT0WUPD;hQi=>
RXF393	NF\jfI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MVvJR\|UxRTJ7LkK5NFYh\|ryP	M2TVb\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QDZ5OD:nQnNCVkeHUkyvZV4>
P30-OHK	Mnv0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			M2C3RWlEPTB;MkmuN\|A1QCEQvF2=	M1TmS\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QDZ5OD:nQnNCVkeHUkyvZV4>
Ca9-22	NWjWW3Q5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NUWybnJFUUN3ME2yPU41Ojl7IN88US=>	NFW3RWo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
RT-112	NEPZdmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			M3Hoe2lEPTB;MkmuOFYyOSEQvF2=	MnnqQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg5Pjd6Lze+V2FPT0WUPD;hQi=>
ES1	M1;lOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MkXpTWM2OD1{OT64OVQ1KM7:TR?=	MYO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFg3PzhxJ{7TRW5ITVJ:L3G+
HCE-4	MlfwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NV\UeId6UUN3ME2yPU45Pzh4IN88US=>	MXO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFg3PzhxJ{7TRW5ITVJ:L3G+
AM-38	NF21WFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NH[2XW1KSzVyPUOwMlA3ODZizszN	NVHBfZZGRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh6Nke4M{c,W0GQR1XSQE9iRg>?
AsPC-1	M33ZRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NXr1O4w4UUN3ME2zNE45ODV\|IN88US=>	NETLeVU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
TE-9	NID2NJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NWPLdVZyUUN3ME2zNE45PzN5IN88US=>	M{Tkb\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QDZ5OD:nQnNCVkeHUkyvZV4>
HuP-T4	NXf2d2FrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NXTjbmdbUUN3ME2zNE46PjN6IN88US=>	NX;NeGZTRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh6Nke4M{c,W0GQR1XSQE9iRg>?
LB2518-MEL	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			M{HjbWlEPTB;M{GuNFc1PCEQvF2=	MoHJQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg5Pjd6Lze+V2FPT0WUPD;hQi=>
NCI-H1703	MlrqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MlfBTWM2OD1\|MT6wPVA2KM7:TR?=	NVPPZ5F{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh6Nke4M{c,W0GQR1XSQE9iRg>?
NCI-H2228	M3HrVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MX3JR\|UxRTNzLkS2OVEh\|ryP	MWG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFg3PzhxJ{7TRW5ITVJ:L3G+
SCC-4	NUXORWhkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			Mn:wTWM2OD1\|MT65NVgyKM7:TR?=	M{HrdVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QDZ5OD:nQnNCVkeHUkyvZV4>
KNS-81-FD	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NIfOXGpKSzVyPUOyMlAyOjhizszN	M322VlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QDZ5OD:nQnNCVkeHUkyvZV4>
NTERA-S-cl-D1	Mm\LS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NF7ad25KSzVyPUOyMlA4OzlizszN	M2LRV\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QDZ5OD:nQnNCVkeHUkyvZV4>
Daoy	M2nPbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MkG1TWM2OD1\|Mj6wPFM5KM7:TR?=	MlL4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg5Pjd6Lze+V2FPT0WUPD;hQi=>
ES4	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MlG2TWM2OD1\|Mj6zPVIzKM7:TR?=	NV7wc4xmRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh6Nke4M{c,W0GQR1XSQE9iRg>?
MHH-ES-1	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			M2\JWmlEPTB;M{KuOFg4OiEQvF2=	MV:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFg3PzhxJ{7TRW5ITVJ:L3G+
C-33-A	MmLtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NYnG[YxEUUN3ME2zNk44PzJ6IN88US=>	M1SzUFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QDZ5OD:nQnNCVkeHUkyvZV4>
BHY	M1\HPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			M{HtcmlEPTB;M{KuPVQ6PSEQvF2=	MnP3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg5Pjd6Lze+V2FPT0WUPD;hQi=>
Detroit562	M2m0fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			M4DsTGlEPTB;M{OuOlY2PyEQvF2=	MX68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFg3PzhxJ{7TRW5ITVJ:L3G+
EW-1	M1fhTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			M4XXcmlEPTB;M{OuPVMzOiEQvF2=	M2XFUFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QDZ5OD:nQnNCVkeHUkyvZV4>
NCI-H1395	MmnyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MnzETWM2OD1\|ND6wO\|k6KM7:TR?=	M1jV[lxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QDZ5OD:nQnNCVkeHUkyvZV4>
KM-H2	M4OyVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MX3JR\|UxRTN4LkS3OFMh\|ryP	M1fx[VxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QDZ5OD:nQnNCVkeHUkyvZV4>
NCI-H520	M1[wUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			M3;4cGlEPTB;M{[uO\|U1OSEQvF2=	NHnNTHY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
D-392MG	NYrrW5JsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MXfJR\|UxRTN5LkOzOFQh\|ryP	MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFg3PzhxJ{7TRW5ITVJ:L3G+
NOMO-1	M3HqfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NWrWWGY3UUN3ME2zO{45ODh7IN88US=>	NIXuclI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
TE-6	MnGzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MX3JR\|UxRTN6LkGyOEDPxE1?	MlfzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg5Pjd6Lze+V2FPT0WUPD;hQi=>
HT-3	NVW5R3J2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			M3H2cWlEPTB;M{iuOFQ{PiEQvF2=	NF3ueW89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
RPMI-8226	NX72VW9nT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MWXJR\|UxRTN6Lkm1NVkh\|ryP	NVXXXYZVRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh6Nke4M{c,W0GQR1XSQE9iRg>?
U251	M1XXNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NIXacYZKSzVyPUO5MlAyOjRizszN	MnPuQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg5Pjd6Lze+V2FPT0WUPD;hQi=>
GCT	M2nYb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MVzJR\|UxRTN7LkG4OVIh\|ryP	MWO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFg3PzhxJ{7TRW5ITVJ:L3G+
A431	MlrJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			Mof0TWM2OD1\|OT6xPFk1KM7:TR?=	MoLZQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg5Pjd6Lze+V2FPT0WUPD;hQi=>
TE-12	NI[1U4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MYjJR\|UxRTN7LkK0OFgh\|ryP	MVO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFg3PzhxJ{7TRW5ITVJ:L3G+
HMV-II	NV;hfndZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			M{jRNGlEPTB;M{muOVA1PyEQvF2=	NUfaSnk3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh6Nke4M{c,W0GQR1XSQE9iRg>?
IST-MES1	MoDtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MV7JR\|UxRTRyLkG1NFIh\|ryP	M1T0cVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QDZ5OD:nQnNCVkeHUkyvZV4>
SW13	NFm3RVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MWTJR\|UxRTRyLkWxPUDPxE1?	MnrkQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg5Pjd6Lze+V2FPT0WUPD;hQi=>
SF295	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			Mke3TWM2OD12MD64NFY3KM7:TR?=	NHLHdHo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
MDA-MB-157	Ml7aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MXzJR\|UxRTRyLkm0OlIh\|ryP	M3LCWVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QDZ5OD:nQnNCVkeHUkyvZV4>
TE-1	M1njc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NYHsPIhGUUN3ME20NU45PzF2IN88US=>	M3niblxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QDZ5OD:nQnNCVkeHUkyvZV4>
HuCCT1	NGHlenVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NEHac4xKSzVyPUSyMlUzQDlizszN	NFXVPHY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
KYSE-510	NXTJR\|JRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NX7Tc5lTUUN3ME20N{4yPzV2IN88US=>	NGrwfmg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
NCI-H358	MmC4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NIm0[lJKSzVyPUS0MlA{ODRizszN	Mlu4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg5Pjd6Lze+V2FPT0WUPD;hQi=>
SW900	M3TRW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NHXZXHlKSzVyPUS0MlA4PThizszN	MWO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFg3PzhxJ{7TRW5ITVJ:L3G+
CAS-1	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NGLnXnpKSzVyPUS0MlA6QTFizszN	NFrXUGM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
TE-8	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MWnJR\|UxRTR2LkW2OVgh\|ryP	M1fUZ\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QDZ5OD:nQnNCVkeHUkyvZV4>
P12-ICHIKAWA	NXLRVXdFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MmTMTWM2OD12ND62NVEzKM7:TR?=	NEjlPWw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
YKG-1	NXLDfot4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NYfSe5FzUUN3ME20OE44QDFizszN	MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFg3PzhxJ{7TRW5ITVJ:L3G+
SNU-C2B	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			Mnq0TWM2OD12ND63PVA{KM7:TR?=	MXy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFg3PzhxJ{7TRW5ITVJ:L3G+
LCLC-103H	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MmfLTWM2OD12ND64O\|A{KM7:TR?=	NWC0U3RlRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh6Nke4M{c,W0GQR1XSQE9iRg>?
U-87-MG	NECxVotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NIXiRlJKSzVyPUS1MlExOjJizszN	Mnj0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg5Pjd6Lze+V2FPT0WUPD;hQi=>
HAL-01	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MoixTWM2OD12NT6xN\|c6KM7:TR?=	MnXZQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg5Pjd6Lze+V2FPT0WUPD;hQi=>
OVCAR-8	MoS1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NX7SO2hWUUN3ME20OU4{PTZ2IN88US=>	NXrQb2pJRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh6Nke4M{c,W0GQR1XSQE9iRg>?
KYSE-150	M{XHXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NVHESGFrUUN3ME20O{4yODV{IN88US=>	M{PpWFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QDZ5OD:nQnNCVkeHUkyvZV4>
OE33	MnHPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			M2n4eWlEPTB;NEeuNVQzQSEQvF2=	MlLZQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg5Pjd6Lze+V2FPT0WUPD;hQi=>
CAL-62	M2\jbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MWPJR\|UxRTR5LkSwOlgh\|ryP	NIPoV3A9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
TCCSUP	NEDCeWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NFvQXlhKSzVyPUS3MlYzPjRizszN	NHXubmo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
H4	NFTUR3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MknCTWM2OD12Nz62OlIyKM7:TR?=	M3XwXFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QDZ5OD:nQnNCVkeHUkyvZV4>
CP66-MEL	NF\oO4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			M{fRTGlEPTB;NEiuNFcxPCEQvF2=	NFWwT3Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
SNB75	MoqzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			M4Pp[mlEPTB;NEiuNVg4PCEQvF2=	MoPEQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg5Pjd6Lze+V2FPT0WUPD;hQi=>
Mo-T	NWL2XnhbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NGLT[\|ZKSzVyPUS4MlI4QSEQvF2=	NVHHR5g{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh6Nke4M{c,W0GQR1XSQE9iRg>?
BT-549	Mnm5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MYLJR\|UxRTR6LkO3Nlkh\|ryP	NFv6bFg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
IGR-1	MlnZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NYrlO21qUUN3ME20PE43PjR3IN88US=>	MoHTQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg5Pjd6Lze+V2FPT0WUPD;hQi=>
NCI-H1299	NU\temJDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NE\5VJVKSzVyPUS4MlczPDhizszN	M{jzc\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QDZ5OD:nQnNCVkeHUkyvZV4>
ALL-PO	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MUjJR\|UxRTR7LkmyOlgh\|ryP	MVW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFg3PzhxJ{7TRW5ITVJ:L3G+
CLL	Mnf5SpVv[3Srb36gZZN{[Xl?			M{nD[mlvcGmkaYTpc44hd2ZiRF7BMXBMKGG3dH;wbI9{eGixconsZZRqd25iYYSgV4VzOjB3NjDy[ZNq\HWnIHnuJIh2dWGwIFPMUEBk\WyuczDifUBY\XO2ZYLuJIJtd3RibXX0bI9lNCCLQ{WwJF0hOC5yMzFOwG0v	NHzkOVU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkizOVg4OCd-MkK4N\|U5PzB:L3G+
HeLa	MnLvSpVv[3Srb36gZZN{[Xl?			NGC5VXpKdmirYnn0bY9vKG:oIFTORU1RUyCjdYTvdIhwe3Cqb4L5cIF1cW:wIHH0JHMzODV4IHnuJIh2dWGwIFjlUIEh[2WubIOsJGVEPTBiPTCwMlIyOiEQvF2u	NWi3U4w6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4OVU5OzZpPkKzPFU2QDN4PD;hQi=>
CHO	MXXGeY5kfGmxbjDhd5NigQ>?			MmDITY5pcWKrdHnvckBw\iCqdX3hckBGWkdiZYjwdoV{e2WmIHnuJINqe2Gycnnk[UB1emWjdHXkJGNJVyClZXzsd{BjgSCLb36gW49zc3NiYYPzZZktKEmFNUCgQUAyPCEQvF2u	NW[1dYlVRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4OVU5OzZpPkKzPFU2QDN4PD;hQi=>
A673	NVu4VY17eUiWUzDhd5NigQ>?			MmTodWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKEF4N{OgZ4VtdHN?	M1[ySVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
DAOY	M4nOS5FJXFNiYYPzZZk>			NHXGXFFyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiRFHPXUBk\Wyucx?=	MVO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
Saos-2	NXzMfXRieUiWUzDhd5NigQ>?			NUXEPFljeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IGPhc5MuOiClZXzsdy=>	M2TI[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
BT-37	MVrxTHRUKGG\|c3H5			M3zURZFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCEVD2zO{Bk\Wyucx?=	MWC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
RD	MmPwdWhVWyCjc4PhfS=>			NUfUcZpMeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IGLEJINmdGy\|	M3XnN\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
BT-12	MlXRdWhVWyCjc4PhfS=>			MkL6dWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKEKWLUGyJINmdGy\|	MVW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
MG 63 (6-TG R)	MkHpdWhVWyCjc4PhfS=>			NHr3V2dyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiTVegOlMhMDZvVFegVkkh[2WubIO=	NHnVRpI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
NB1643	MkDJdWhVWyCjc4PhfS=>			NXnlelVyeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IF7CNVY1OyClZXzsdy=>	MWq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
OHS-50	MlLSdWhVWyCjc4PhfS=>			M161TJFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCRSGOtOVAh[2WubIO=	M4XENlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
SJ-GBM2	NXq3OWpjeUiWUzDhd5NigQ>?			NEn4cmRyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiU1qtS2JOOiClZXzsdy=>	MonqQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
SK-N-MC	MYHxTHRUKGG\|c3H5			NVryT3NZeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IGPLMW4uVUNiY3XscJM>	MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
NB-EBc1	Mo\RdWhVWyCjc4PhfS=>			NH\YVoJyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiTlKtSWJkOSClZXzsdy=>	MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
LAN-5	NWLRc5lZeUiWUzDhd5NigQ>?			M{GzT5FJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCOQV6tOUBk\Wyucx?=	NWrEeXFLRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
Rh18	MUHxTHRUKGG\|c3H5			M{C0c5FJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCUaEG4JINmdGy\|	M4\BTlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
INA-6	NFL3cphHfW6ldHnvckBie3OjeR?=	M3eyVlExKHWP	NUTP[3JCPCCqcoO=	Mne1TY5pcWKrdHnvckBw\iCqZXH0JJNpd2OtIILld5BwdnOnIHnuJIh2dWGwIFnORU03KGOnbHzzJIF{e2W\|c3XkJIF{KHKnZIXjeIlwdiCrbjDIV2YuOSCvZXTpZZRm\CC3cILl[5Vt[XSrb36gc4YhfGinIFjTVFczKHC{b4TlbY4h\XiycnXzd4lwdiCjdDCxNEB2VSCycnXpcoN2[mG2ZXSg[o9zKDRiaILzJIZwdGyxd3XkJIJ6KEiVUEmwJIlvcGmkaYTvdkBidmRiSGPSJIlv\HWlZYKgUnZRNUGXWUmyNkBi\GSrdHnvckBu\WG\|dYLl[EBi\nSncjC0JIhz	Mo\nQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh2NUO5N\|EoRjJ6NEWzPVMyRC:jPh?=
INA-6	MlvySpVv[3Srb36gZZN{[Xl?	NV7mcJdFOTBidV2=	NH7WPVM1KGi{cx?=	MV7Jcohq[mm2aX;uJI9nKGinYYSgd4hw[2ticnXzdI9ve2ViaX6gbJVu[W5iSV7BMVYh[2WubIOgZZN{\XO\|ZXSgZZMhemWmdXP0bY9vKGmwIFjTSk0yKG2nZHnheIVlKHWycnXneYxifGmxbjDv[kB1cGViSGPQO\|IhdVKQQTDlfJBz\XO\|aX;uJIF1KDFyIIXNJJBz\WmwY4XiZZRm\CCob4KgOEBpenNiZn;scI94\WRiYomgTHNRQTBiaX7obYJqfG:{IHHu[EBJW1JiaX7keYNmeiCQVmCtRXV[QTJ{IHHk[Il1cW:wIH3lZZN2emWmIHHmeIVzKDRiaILzJII>	MX28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDR3M{mzNUc,Ojh2NUO5N\|E9N2F-
INA-6	MlTzSpVv[3Srb36gZZN{[Xl?	MXyxNEB2VQ>?	MmX4OEBpenN?	MlzLSI94dnKnZ4XsZZRqd25ib3[gUnZRNUGXWUmyNk1qdmS3Y3XkJGhUTi1zIIDyc5RmcW5iZYjwdoV{e2mxbjDpckBpfW2jbjDJUmEuPiClZXzsd{BifCBzMDD1UUBxemWrbnP1ZoF1\WRiZn;yJFQhcHK\|IH\vcIxwf2WmIHL5JG5XWC2DVWm5NlIh[WSmaYTpc44hdWWjc4Xy[YQh[W[2ZYKgOEBpenNiYomgW4V{fGW{bjDicI91KG2ndHjv[C=>	NUmyc\|hjRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki0OVM6OzFpPkK4OFU{QTNzPD;hQi=>
INA-6	NEPwcm5HfW6ldHnvckBie3OjeR?=	M{LSe\|ExKHWP	MYS0JIhzew>?	NWfIXpJXUW6qaXLpeIlwdiCxZjDOWnAuSVW\OUKyMYlv\HWlZXSgTHNHNTFicHjvd5Bpd3K7bHH0bY9vKGmwIHj1cYFvKEmQQT22JINmdGy\|IHH0JFExKHWPIIDy[Ylv[3WkYYTl[EBnd3JiNDDodpMh\m:ubH;3[YQh[nliTm\QMWFWYTl{MjDh[IRqfGmxbjDt[YF{fXKnZDDh[pRmeiB2IHjyd{BjgSCZZYP0[ZJvKGKub4SgcYV1cG:m	MYi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDR3M{mzNUc,Ojh2NUO5N\|E9N2F-
INA-6	NUjiXmNCTnWwY4Tpc44h[XO\|YYm=	MmLXNVAhfU1?	NUL6UYlJPCCqcoO=	NYXh[213TG:5boLl[5Vt[XSrb36gc4YhVl[SLVHVXVkzOi2rbnT1Z4VlKEiVRj2xJI1TVkFiZYjwdoV{e2mxbjDpckBpfW2jbjDJUmEuPiClZXzsd{BifCBzMDD1UUBxemWrbnP1ZoF1\WRiZn;yJFQhcHK\|IH\vcIxwf2WmIHL5JG5XWC2DVWm5NlIh[WSmaYTpc44hdWWjc4Xy[YQh[W[2ZYKgOEBpenNiYomgVnQuWEOUIH3leIhw\A>?	MXO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDR3M{mzNUc,Ojh2NUO5N\|E9N2F-

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	p-DNA-PKcs / DNA-PKcs / p-ATM / ATM / p-ATR / ATR / Ku70 / p-CHK1 / p-CHK2/ p-AKT / RAD51; PubMed: 29344644 Oncol Rep SUNE1 cells were irradiated with 5 Gy in the presence or absence of NU7441 (2 µM). The expression of cell cycle checkpoint proteins and double strand break repair proteins was assayed by western blot analysis at 6 or 12 h post-IR. p-mTOR(Ser2448) / mTOR / p-S6K(Thr389); PubMed: 25714019 Oncotarget Phosphorylation of mTOR and p70S6K were detected by Western blot analysis 24 hours after treatment.	29344644 25714019

In vivo

NU7441 intraperitoneally administrated at dose of 10 mg/kg maintains for at least 4 hours shows nontoxic and increases etoposide-induced tumor growth delay 2-fold in mice bearing SW620 xenografts. ^[2]

Protocol

Cell Research:

^[2]

- Collapse

Cell lines: SW620, LoVo, V3-YAC and V3 cells
Concentrations: 0.5 μM or 1 μM
Incubation Time: 17 hours
Method:
The effect of NU7441 on cellular survival following exposure to etoposide, doxorubicin, and ionizing radiation is measured in SW620, LoVo, V3, and V3-YAC cells by clonogenic assays. Briefly, growing cells in six-well plates or 6-cm dishes are exposed to etoposide or doxorubicin with or without NU7441 (0.5 or 1.0 μM) for 16 hours. For radiosensitization studies, NU7441 is added to the cells 1 hour before irradiation. V3 and V3-YAC cells are exposed to γ-irradiation (3.1 Gy/min ¹³⁷Cesium). SW620 and LoVo are exposed to X-irradiation (2.9 Gy/min at 230 kV, 10 mA) due to the equipment available. After irradiation, the cells are incubated with or without NU7441 for a further 16 hours. Cells are then harvested by trypsinization, counted, and seeded into 10-cm diameter Petri dishes at densities varying from 100 to 10⁵ per dish in drug-free medium for colony formation. Colonies are stained with crystal violet after 10 to 14 days and counted with an automated colony counter. The survival reduction factor (SRF) is calculated as the surviving fraction of cells in the absence of NU7441 divided by the surviving fraction of cells in the presence of NU7441 for any given dose or concentration of cytotoxic agent. The dose modification ratio (DMR90) is calculated as the concentration/dose of cytotoxic agent required to kill 90% of the cells in the absence of NU7441 divided by the concentration/dose of cytotoxic agent required to kill 90% of the cells in the presence of NU7441.

(Only for Reference)

Animal Research:

^[2]

- Collapse

Animal Models: Female rude mice bearing SW620 xenografts
Dosages: 10 mg/kg
Administration: Intraperitoneally administrated
(Only for Reference)

References

- Collapse

Solubility (25°C)

In vitro	DMSO	4 mg/mL warmed (9.67 mM)
	Water	Insoluble
	Ethanol	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 5% DMSO+40% PEG 300+5% Tween 80+50% ddH2O For best results, use promptly after mixing.	0.5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download NU7441 (KU-57788) SDF

Molecular Weight	413.49
Formula	C₂₅H₁₉NO₃S
CAS No.	503468-95-9
Storage	3 years-20°C powder 2 years-80°C in solvent
Synonyms	N/A
Smiles	C1COCCN1C2=CC(=O)C3=C(O2)C(=CC=C3)C4=CC=CC5=C4SC6=CC=CC=C56

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage

mg/kg

Average weight of animals

Dosing volume per animal

Number of animals

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO+ % + % Tween 80+ % ddH₂O

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take μL DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
Could you please suggest formulations of the drug for in vivo injection?
Answer:
We tested the following formulation for in vivo use, 4% DMSO+30% PEG 300+5% Tween 80+ddH2O up to 1mg/mL. It is a clear solution.
Question 2:
Previous aliquots were clear and colorless while this time, it becomes yellow when the powder was dissolved in DMSO? Could you advice on this?
Answer:
Slight color variation due to different processing is normal and usually doesn't interfere with the function.

DNA-PK Signaling Pathway Map

DNA-PK Inhibitors with Unique Features

Non-specific DNA-PK Inhibitor

PI-103 : DNA-PK, IC50=23 nM; p110α/β/δ/γ, IC50=2 nM/3 nM/3 nM/15 nM; mTOR, IC50=30 nM.
Most Potent DNA-PK Inhibitor

PIK-75 : DNA-PK, IC50=2 nM.
Newest DNA-PK Inhibitor

KU-0060648 : Dual inhibitor of DNA-PK and PI3Kα, PI3Kβ, PI3Kδ with IC50 of 8.6 nM and 4 nM, 0.5 nM, 0.1 nM respectively, less inhibition of PI3Kγ with IC50 of 0.59 μM.
Classic DNA-PK Inhibitor

NU7026 : Potent DNA-PK inhibitor with IC50 of 0.23 μM, 60-fold selective for DNA-PK than PI3K and inactive against both ATM and ATR.

Related DNA-PK Products

CHIR-99021 (CT99021) ^New

CHIR-99021 (CT99021) is a GSK-3α and GSK-3β inhibitor with IC50 of 10 nM and 6.7 nM, respectively. CHIR99201 does not exhibit cross-reactivity against cyclin-dependent kinases (CDKs) and shows a 350-fold selectivity toward GSK-3β compared to CDKs. CHIR99021 functions as a Wnt/β-catenin activator and induces autophagy.
Dorsomorphin (Compound C) ^New

Dorsomorphin (Compound C, BML-275) is a potent, reversible, selective AMPK inhibitor with K_i of 109 nM in cell-free assays, exhibiting no significant inhibition of several structurally related kinases including ZAPK, SYK, PKCθ, PKA, and JAK3. Dorsomorphin selectively inhibits the BMP type I receptors ALK2, ALK3 and ALK6. Dorsomorphin is used in promoting specific cell differentiation and inducing cancer cell line autophagy. For animal testing, the water-soluble S7306 Dorsomorphin (Compound C) 2HCl is recommended.
MHY1485 ^New

MHY1485 is a potent, and cell-permeable mTOR activator, and also potently inhibits autophagy.
NU7026

NU7026 (LY293646) is a potent DNA-PK inhibitor with IC50 of 0.23 μM in cell-free assays, 60-fold selective for DNA-PK than PI3K and inactive against both ATM and ATR. NU7026 enhances G2/M cell arrest and apoptosis.
KU-0060648

KU-0060648 is a dual inhibitor of DNA-PK and PI3Kα, PI3Kβ, PI3Kδ with IC50 of 8.6 nM and 4 nM, 0.5 nM, 0.1 nM respectively, less inhibition of PI3Kγ with IC50 of 0.59 μM.
Rapamycin (AY-22989)

Rapamycin (AY-22989, Rapamune, Sirolimus, NSC-2260804) is a specific mTOR inhibitor with IC50 of ~0.1 nM HEK293 cells.
MK-2206 2HCl

MK-2206 2HCl is a highly selective inhibitor of Akt1/2/3 with IC50 of 8 nM/12 nM/65 nM in cell-free assays, respectively; no inhibitory activities against 250 other protein kinases observed. MK-2206 2HCl induces autophagy and apoptosis in cancer cells. Phase 2.

Features:The first allosteric small molecule inhibitor of Akt to enter clinical development.
CHIR-99021 (CT99021) HCl

CHIR-99021 (CT99021) HCl is hydrochloride of CHIR-99021, which is a GSK-3α/β inhibitor with IC50 of 10 nM/6.7 nM; CHIR-99021 shows greater than 500-fold selectivity for GSK-3 versus its closest homologs Cdc2 and ERK2. CHIR-99021 is a potent pharmacological activators of the Wnt/beta-catenin signaling pathway. CHIR-99021 significantly rescues light-induced autophagy and augments GR, RORα and autophagy-related proteins.
LY294002

LY294002 (SF 1101, NSC 697286) is the first synthetic molecule known to inhibit PI3Kα/δ/β with IC50 of 0.5 μM/0.57 μM/0.97 μM, respectively; more stable in solution than Wortmannin, and also blocks autophagosome formation. It not only binds to class I PI3Ks and other PI3K-related kinases, but also to novel targets seemingly unrelated to the PI3K family. LY294002 also inhibits CK2 with IC50 of 98 nM. LY294002 is a non-specific DNA-PKcs inhibitor and activates autophagy and apoptosis.
3-Methyladenine (3-MA)

3-Methyladenine (3-MA, NSC 66389) is a selective PI3K inhibitor for Vps34 and PI3Kγ with IC50 of 25 μM and 60 μM in HeLa cells; blocks class I PI3K consistently, whereas suppression of class III PI3K is transient, and also blocks autophagosome formation. 3-Methyladenine (3-MA) is successfully used to suppress mitophagy. Solutions of 3-MA are best fresh-prepared by heating.

Choose Your Country or Region

By Signaling Pathways

By product type

NU7441 (KU-57788)